50,000 Dogs and the Search for the Reason They Age

The oldest reliably documented dog was an Australian cattle dog named Bluey, who lived to 29 years and 5 months before being euthanised in 1939. His record stood unchallenged for decades, a statistical outlier so extreme it had almost become folklore. Then, in 2023, a Portuguese dog named Bobi was briefly certified by Guinness World Records as having lived to 31 — a claim subsequently called into question by veterinary record investigators. The longevity record, like the biology of ageing it reflects, is more contested than it appears.

Most dogs do not approach these ages. A medium-sized dog lives roughly 10–13 years; a Great Dane may be elderly at seven. The variation in lifespan across breeds is itself one of the most striking phenomena in mammalian biology — a 70 kg Mastiff and a 5 kg Chihuahua may share 99.9 percent of their genome, but their expected lifespans differ by a factor of nearly two. No other domestic species exhibits anything close to this. It makes the dog, in the view of a growing number of geroscientists, one of the most valuable natural laboratories for understanding why living things age at all.

The largest study of its kind

In 2018, a team led by Daniel Promislow at the University of Washington and Kate Creevy at Texas A&M launched what they called the Dog Aging Project — a longitudinal study designed to enrol tens of thousands of dogs across the United States and follow them throughout their lives. The ambition was unprecedented: not a clinical trial, not a single-breed study, not a snapshot survey, but a continuous, population-scale, multi-omic investigation of how a mammalian species ages.

The dogs' owners complete detailed annual health surveys — the Health and Life Experience Survey (HLES) — covering diet, exercise, veterinary history, medications, living environment, and owner demographics. A subset of enrolled dogs undergo a deeper phenotyping protocol including physical examination, blood panels, urinalysis, cognitive testing, and, crucially, biosampling: DNA for genomic analysis, blood for proteomics and metabolomics, faecal samples for microbiome profiling. The result is a dataset of unusual richness, built not in a laboratory but in the homes of ordinary American families, by ordinary dogs living ordinary lives.

Why dogs and not mice

The choice of the dog as a model organism for ageing research is not arbitrary. Laboratory mice and rats have dominated biomedical ageing research for decades, but they have significant limitations as proxies for human ageing. Their lifespan is too short, their living conditions too artificial, their diseases too different. Dogs, by contrast, share our homes and our pollutants, eat our food (or food similar to it), develop many of the same age-related diseases — cancer, cognitive dysfunction, heart disease, arthritis, kidney disease — and do so spontaneously, without the genetic manipulation required to induce these conditions in a mouse. They live long enough for longitudinal study but short enough for research careers to span multiple dog lifespans.

The body-size–lifespan paradox is itself a research priority. Within most mammalian species, larger individuals live longer — an elephant outlives a mouse. Within dogs, the opposite holds: larger breeds die younger. The molecular mechanisms underlying this reversal are not fully understood, but research suggests that elevated growth hormone and IGF-1 signalling in large breeds accelerates cellular senescence and increases cancer risk. Giant breeds may pay for their size with accelerated ageing.

What the project has already found

The Dog Aging Project published its first major findings from the HLES cohort in a 2022 paper in PLOS ONE, describing the baseline health and demographic characteristics of over 27,000 enrolled dogs. Among the associations identified: dogs living in rural environments showed lower rates of some chronic conditions than urban dogs; dogs sharing their owner's bed had different health profiles from dogs sleeping elsewhere; obesity — flagged in over a third of enrolled dogs by their owners — was associated with a broad range of adverse health outcomes.

A separate arm of the project, the Trailblazers study, is investigating the drug rapamycin as a potential geroprotector in dogs — building on laboratory findings that rapamycin extends lifespan in mice and preliminary data suggesting it may slow cardiac ageing in middle-aged dogs. If rapamycin proves safe and effective in dogs at scale, the implications for translational medicine in humans would be significant.

The dog as mirror

There is something philosophically vertiginous about the Dog Aging Project that is easy to miss in the scientific literature. The study's deeper subject is not really dogs. It is ageing — the universal biological process by which entropy accumulates in cells, tissues, and systems until they can no longer maintain order against the world. Dogs are the vehicle. The destination is an understanding of that process that might, eventually, be applied to the species that built the study in the first place.

There is a version of this story that is purely scientific — the datasets, the biomarkers, the mTOR pathway. But there is another version, the one that explains why the Dog Aging Project has recruited over 50,000 dogs from ordinary households: the owners signed their dogs up because they love them, and they want to understand why those dogs will, in most cases, outlive them by only a decade or so, and be gone.

Science and grief are not the same thing. But they can, occasionally, point in the same direction. The dog that sleeps at the foot of your bed is also, if you chose to enrol it, a participant in one of the most ambitious longitudinal studies in the history of biology. The grey muzzle contains data. The data may, in time, tell us something about our own grey muzzles. This is the bargain the Dog Aging Project is asking 50,000 families to make. So far, they have said yes.